Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by eddy0505on Aug 07, 2018 6:07pm
156 Views
Post# 28424065

RE:Preliminary short form prospectus filing

RE:Preliminary short form prospectus filingFrom today’s filed prospectus.... they should get financing or partnership deal I believe..
market for antifungal in billions & growing..

Cost of advancing trials..from today’s filing Aug 7th..


iCo has completed Phase I trials of the Oral Amp B Delivery System. Assuming initiation of later staged trials in 2018, we could expect filing for drug approval as early as 2021. We currently estimate that costs for a 90 patient Phase II study would be approximately US$2,000,000 and subsequent Phase III anti-fungal trials would be approximately US$5,000,000 to US$10,000,000 depending on whether one or two pivotal studies is required. Phase III studies would likely involve 100-150 patients per treatment arm. VL trials may be cheaper if conducted in a developing world setting. Phase III may involve roughly 600 patients. The Company intends to seek additional grant monies to offset clinical study costs. Groups sponsoring such work include Drugs for Neglected Diseases Initiative, the Bill and Melinda Gates Foundation and a number of other government sponsored initiatives.
<< Previous
Bullboard Posts
Next >>